Audit and Research

The number of corneal transplant surgeries performed, success rates, diagnoses made and a comparison of success rates and survival rates, between procedures (PK versus ALK versus EK), are shown in Figures 3.1 to 3.4.

Penetrating Keratoplasty (PK) is a form of microsurgery in which the central portion of the damaged or cloudy cornea is removed completely, and a clear and healthy donor cornea is sutured in its place with very fine microsurgical nylon sutures. However, lamellar surgery such as Endothelial Keratoplasty (EK) and Anterior Lamellar Keratoplasty (ALK) have become the methods of choice for many cornea diseases.

In EK, the diseased endothelial cells, present on the innermost layer of the cornea, are replaced through a small keyhole incision with techniques such as DSAEK and DMEK. In ALK, diseased outer layers of the cornea are removed and replaced, while preserving the remaining healthy corneal layers. These techniques result in stronger and more stable corneas, and lower graft rejection and graft failure rates compared to PK surgery.

ceed

The Singapore Cornea Transplant Study at SNEC demonstrate the superior long-term graft survival of lamellar keratoplasty compared to PK. ALK was associated with the highest cumulative probability of survival in the medium term, followed by EK, and finally PK.

Benchmarks of success

TABLE 3.1. Comparison of SNEC audit data with other corneal graft registries/studies
Procedure	Name of corneal graft registry/study	Graft survival (%)
PK	SNEC audit data	92/67 (1-year/5-year)
	Australian Corneal Graft Registry (Williams et al., 2015)	94/68 (1-year/6-year)
	Cornea Donor Study (USA) (Cornea Donor Study Investigator Group, 2008)	97/86 (1-year/5-year)
	United Kingdom Transplant Database (Kasbekar, Jones, Ahmad, Larkin, & Kaye, 2014)	92 (5-year)
ALK	SNEC audit data	96/94/91 (1-year/3-year/5-year)
	Australian Corneal Graft Registry (Williams et al., 2015)	93/87 (1-year/3-year)
	United Kingdom Transplant Database (Kasbekar et al., 2014)	90 (5-year)
DSAEK (All diagnoses)	Singapore Corneal Transplant Study (Ang, Soh, Htoon, Mehta & Tan, 2016)	79.4 (5-year)
EK (Fuchs' dystrophy)	Singapore Corneal Transplant Study (Ang et al., 2012)	93 (3-year)
	Australian Corneal Graft Registry (Williams et al., 2015)	96 (3-year)

References

Ang, M., Mehta, J, S., Lim, F., Bose, S., Htoon, H.M., & Tan, D. (2012). Endothelial cell loss and graft survival after Descemet’s stripping automated endothelial keratoplasty and penetrating keratoplasty. Ophthalmology, 119, 2239-2244.
Ang, N., Soh, Y., Htoon, H. M., Mehta, J. S., & Tan, D. (2016). Five-year graft survival comparing Descemet stripping automated endothelial keratoplasty and penetrating keratoplasty. Ophthalmology, 123, 1646-1652.
Cornea Donor Study Investigator Group. (2008). The effect of donor age on corneal transplantation outcome results of the cornea donor study. Ophthalmology, 115, 620-626.
Kasbekar, S. A., Jones, M. N., Ahmad, S., Larkin, D. F., & Kaye, S. B. (2014). Corneal transplant surgery for keratoconus and the effect of surgeon experience on deep anterior lamellar keratoplasty outcomes. American Journal of Ophthalmology, 158, 1239-1246.
Khor, W. B., Han, S. B., Mehta, J. S., & Tan, D. T. (2013). Descemet stripping automated endothelial keratoplasty with a donor insertion device: clinical results and complications in 100 eyes. American Journal of Ophthalmology, 156, 773-779.
Mehta, J. S., Por, Y. M., Poh, R., Beuerman, R. W., & Tan, D. (2008). Comparison of donor insertion techniques for descemet stripping automated endothelial keratoplasty. Archives of Ophthalmology, 126, 1383-1388.
Tan, D. T., Tay, A. B., Theng, J. T., Lye, K. W., Parthasarathy, A., Por, Y. M., Liu, C. (2008). Keratoprosthesis surgery for end-stage corneal blindness in Asian eyes. Ophthalmology, 115, 503-510.
Williams, K. A., Keane, M, C., Galettis, R. A., Jones, V. J., Mills, R. A., & Coster, D. J. (2015). The Australian Corneal Graft Registry 2015 Report. Retrieved from https://www.flinders.edu.au/medicine/sites/ophthalmology/clinical/the-australian-corneal-graft-registry.cfm

Back to Clinical Interests

Our Care Team

Recent News

Research Formosa Pharmaceuticals and SERI Partner to Advance Novel Ophthalmic Formulations for Corneal Diseases SINGAPORE / TAIPEI — April 30, 2026 – Formosa Pharmaceuticals, Inc. (“Formosa”, 6838.TW) and the Singapore Eye Research Institute (“SERI”) are pleased to announce a strategic research collaboration to develop next-generation ophthalmic formulations. This partnership will leverage Formosa’s proprietary APNT® (Active Pharmaceutical (ingredient) Nanoparticle Technology) and SERI’s world-class clinical research expertise, led by renowned Clinician Scientist, Associate Professor Yu-Chi Liu, MD, PhD. The collaboration aims to address significant unmet needs in the treatment of corneal and ocular surface diseases. By combining innovative and clinically validated drug delivery platforms with deep clinical insights, the joint effort seeks to enhance the efficacy, bioavailability, and safety of topical ocular therapies, bringing new therapies to clinical practice. Synergy of Innovation and Clinical Excellence A/Prof Yu-Chi Liu, clinician scientist at Singapore National Eye Center and Principal Investigator at SERI, brings extensive experience in corneal neuropathy and translational medicine to the collaboration. Her recent work in diabetic keratopathy and ocular surface inflammation will be pivotal in guiding the development of formulations targeting complex anterior segment conditions. "Collaborating with Formosa Pharmaceuticals allows us to bridge the gap between benchside innovation and bedside application," said A/Prof. Yu-Chi Liu. "Our goal is to utilize advanced formulation technologies like APNT to create treatments that are not only more effective but also less burdensome for patients suffering from ocular conditions." Leveraging APNT® Technology Formosa Pharmaceuticals’ APNT® platform specializes in reducing the particle size of active pharmaceutical ingredients (APIs) to stable, uniform nanoparticles. This technology is a hallmark of Formosa's development pipeline, offering a powerful solution for improving the delivery of poorly soluble drugs to the target tissues and organs. "We are honored to work alongside Professor Liu and her distinguished team at SERI," said Erick Co, President & CEO of Formosa Pharmaceuticals. "Initial efforts have confirmed compatibility of APNT and SERI’s research models and prompt us to extend our partnership. SERI’s reputation for excellence in vision research, backed by their comprehensive capabilities and facilities, are unparalleled. Together, we are excited to translate the research findings into better clinical outcomes."

30 Apr 2026 Read Story

Education Singapore National Eye Centre and Singapore Polytechnic collaborate to strengthen optometrists’ role in community eye care The partnership will see both parties co-develop the Clinical Decision-Making in Community Optometry training programme for practicing community optometrists to build on their competencies to deliver quality eye care in the community.

05 Mar 2026 Read Story

View All News

Corneal & External Eye Disease